Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.61 |
| ▸ | TACR3 | P29371 | 6/20 | 0.53 |
| ▸ | TACR2 | P21452 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797426 | 1.00 | KDM4E (0.71) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL18117441 | 0.92 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL4001534 | 0.85 | KDM4E (0.61) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL19576125 | 0.83 | KDM4E (0.77) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL14392390 | 0.82 | KCNK3 (0.53) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL5616253 | 0.82 | KCNA5 (0.60) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL5072662 | 0.82 | KCNA5 (0.60) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL6366571 | 0.81 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL28481443 | 0.80 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAHPGDTSHR | |
| SCHEMBL6366652 | 0.80 | MEN1 (0.71) | KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385820-B1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-1399423-B9 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-27 | — | — | EP | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1399423-B1 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-7235664-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| CN-1247544-C | Anthranilic acid amides with heteroarylsulfonyl side chains and their use as antiarrhythmic active substances | SANNOFFE AVENTIS DEUTSCHLAND G (DE) | 2006-03-29 | — | — | CN | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| CN-1529695-A | Anthranilic acid amides with heteroarylsulfonyl side chains, method for the production thereof, use thereof as medicaments or diagnostic agents, and pharmaceutical preparations containing said compounds | ������ҽҩ�¹�����˾ | 2004-09-15 | — | — | CN | disclosed |
| EP-1399423-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1385820-A1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | Sanofi-Aventis Deutschland GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20030187033-A1 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| WO-2002100825-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, AND USE THEREOF AS ANTIARRHYTHMIC ACTIVE SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088073-A1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | KDM4E 221/4885ALDH1A1 1867/4885LMNA 455/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | KDM4E 261/4885ALDH1A1 1650/4885LMNA 734/4885 |
| US-20030187033-A1 | Anthranilamides and methods of their use | KCNH1, KCNJ2, KCNH2 | KDM4E 533/4885ALDH1A1 934/4885LMNA 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.